Natalie Holles
2017 - Audentes Therapeutics
In 2017, Natalie Holles earned a total compensation of $3.6M as Senior Vice President, Chief Operating Officer at Audentes Therapeutics, a 668% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $151,410 |
|---|---|
| Option Awards | $3,029,347 |
| Salary | $378,525 |
| Total | $3,559,282 |
Holles received $3M in option awards, accounting for 85% of the total pay in 2017.
Holles also received $151.4K in non-equity incentive plan and $378.5K in salary.
Rankings
In 2017, Natalie Holles' compensation ranked 2,959th out of 14,666 executives tracked by ExecPay. In other words, Holles earned more than 79.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,959 out of 14,666 | 80th |
Division Manufacturing | 1,018 out of 5,772 | 82nd |
Major group Chemicals And Allied Products | 273 out of 2,075 | 87th |
Industry group Drugs | 208 out of 1,731 | 88th |
Industry Biological Products, Except Diagnostic Substances | 39 out of 313 | 88th |
Source: SEC filing on April 27, 2018.
Holles' colleagues
We found three more compensation records of executives who worked with Natalie Holles at Audentes Therapeutics in 2017.